（ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 派發二零二四年末期股息的記錄日期及預扣稅率 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* 根據以色列與股東居住國之間的適用稅收協定而有權享有減免稅率但於股息派付 前尚未取得以色列稅務局批准的股東，可以透過向以色列稅務局提交稅務申報（個 人表格1301及公司表格1214）及相關文件（如身份證文件、稅收居民文件、註冊證 書及稅項扣繳的確認）的方式申請退稅。本公司將於派發二零二四年末期股息後向 以 色 列 稅 務 局 申 請 有 關 稅 項 扣 繳 的 確 認 。 股 東 可 通 過 本 公 司 官 網 網 站 www.sisram-medical.com所示的多種溝通渠道聯繫本公司以獲取有關確認的副 本。於稅務申報時，股東須呈報其於以色列所得的所有收入（倘該股東為以色列稅 收居民，其亦須呈報全球範圍內的收入） ...

董事會會議召開日期 復銳醫療科技有限公司*（「本公司」）董事會（「董事會」）兹宣佈謹定於二零二五年八 月二十日舉行本公司董事會會議，以考慮及通過本公司及其附屬公司截至二零二 五年六月三十日止的六個月中期業績，及派發之中期股息（如有），以及處理任何 其他事項。 代表董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 復銳醫療科技有限公司* 主席 劉毅 香港，二零二五年八月八日 於本公告日期，本公司董事會包括執行董事劉毅先生、Lior Moshe DAYAN先生 及李家宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香生先 生、陳志峰先生、陳怡芳女士及廖啟宇先生。 * 僅供識別 Sisram Medical Ltd ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Sisram Medical Ltd 復銳醫療科技有限公司* 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01696 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | ILS | | 0.01 | ILS | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | | ILS | | 0 | | 本月底結存 | | | 1,000,000,000 | ILS | | 0.01 | ILS | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 本公司知悉市場對其再授權產品RT002（中國境內商標達希斐®，英文商標 DAXXIFY®，通用名DaxibotulinumtoxinA-lanm，以下簡稱「該產品」）於中國內 地的商業化進展持續關注。 復䢇醫療科技有限公司* 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 香港，二零二五年七月二十八日 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生及李家宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香 生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司僅此說明，於本公告日期，該產品在中國內地的商業化工作正穩步推進。 監管申報 ...

Group 1 - The core viewpoint of the report highlights the growth potential of Ruiri Medical Technology, which is expanding its business from energy-based medical aesthetics to a diversified beauty and health ecosystem through acquisitions and market expansion [1] - The global market for energy-based medical devices reached $5.7 billion in 2022, with a projected CAGR of 13.8% from 2023 to 2030, indicating strong growth prospects [1] - North America accounted for 35.4% of the global market in 2022, while the Asia-Pacific region is expected to have a higher growth rate of 15.6% from 2023 to 2030 [1] Group 2 - The company is focusing on product development, channel expansion, and research and development to achieve steady global growth [1] - The product range includes various energy sources such as lasers, intense pulsed light, radiofrequency, ultrasound, plasma, and shockwave, catering to comprehensive beauty needs [1] - The company has established a sales network covering over 110 countries and regions by combining distribution and direct sales strategies, aiming for significant optimization of product pricing and overall performance [1] Group 3 - Long-acting botulinum toxin is expected to gain rapid market acceptance due to its advantages, including a median duration of 6 months and a maximum of 9 months, addressing consumer concerns about frequent injections [2] - The industry is anticipated to accelerate its development phase due to improved policies, consumer education, product technology iterations, and channel penetration [2] - Revenue projections for the company are $395 million, $468 million, and $530 million for 2025, 2026, and 2027, respectively, with corresponding net profits of $31 million, $45 million, and $57 million [2]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][5]. Core Views - The company is leveraging its energy-based medical aesthetics equipment to expand into multiple beauty categories, establishing a diversified ecosystem in the global medical aesthetics market [1][15]. - The long-acting botulinum toxin product, DAXXIFY, is expected to launch in 2025-2026, which could significantly enhance market recognition and sales due to its extended efficacy [3][19]. Summary by Sections Company Overview - The company began its journey in 2013 with the acquisition of Alma Lasers and has since expanded its business from energy-based medical aesthetics to include injection products, dental care, and personal care, enhancing its global market influence [1][15]. Main Business - The company aims to create a comprehensive medical aesthetics industry chain, providing one-stop beauty solutions that encompass energy-based medical aesthetics, injection aesthetics, dental care, and personal care [15][24]. Financial Analysis - The company experienced a temporary decline in revenue growth due to macroeconomic factors and strategic adjustments, with a projected revenue of $3.49 billion in 2024, reflecting a decrease of 2.83% [25][30]. - The net profit is also expected to decline to $0.25 billion in 2024, down 20.23% from the previous year, primarily due to increased sales expenses from transitioning to a direct sales model [25][30]. Energy-Based Equipment - The global market for energy-based medical aesthetics devices reached $5.7 billion in 2022, with a projected CAGR of 13.8% from 2023 to 2030, driven by the growing demand for non-invasive aesthetic procedures [2][44]. - North America is the largest market, accounting for 35.4% of global sales, while the Asia-Pacific region is expected to see the highest growth rate at 15.6% CAGR from 2023 to 2030 [2][44]. Long-Acting Botulinum Toxin - The long-acting botulinum toxin product, DAXXIFY, is anticipated to address consumer concerns regarding frequent injections, with a median duration of effect lasting 6 to 9 months, positioning it favorably in the market [2][3]. Other Business Segments - The company is actively expanding into dental care and personal care, aiming to broaden its long-term growth potential [19][24].

Group 1 - Nanshan Aluminum International (02610.HK) expects a mid-term net profit of approximately $225 million to $265 million for the six months ending June 30, 2025, compared to a net profit of about $159 million for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to an improvement in gross margin, driven by higher alumina prices and relatively stable unit production costs [1] - The average selling price of the company's products for the first half of 2025 is expected to be around $530 per ton, up from approximately $387 per ton in the first half of 2024, but lower than $561 per ton in the second half of 2024 [1] Group 2 - TCL Electronics (01070.HK) anticipates a year-on-year adjusted net profit growth of approximately 45% to 65% for the first half of 2025 [2] - Renrui Talent (06919.HK) expects a mid-term profit attributable to equity holders to increase by 66.7% to 94.1% [2] - China Rare Earth Holdings (03788.HK) reports an increase in total gold resources to 5.07 million ounces [2]

自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈，本公司主要營運附屬公司Alma Lasers Ltd.，已向北美市場推出 Universe （「該產品」），一款基於人工智能的個性化醫療級護膚產品。 該產品為基於人工智能的專業分析軟件，可協助醫生精準地捕捉面部圖像並高效 完成皮膚分析，結合患者皮膚特徵及審美偏好，智能生成個性化護膚配方。 本公司相信，該產品的推出將依托先進的人工智能技術，引領個性化護膚治療的 創新，為後續全球推出奠定堅實的基礎，從而為公司收入結構注入新增長動力， 並進一步强化公司的產品組合和市場競爭力。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 香港，二零二五年七月二十 ...

Market Overview - A-shares rose again on July 10, with the Shanghai Composite Index surpassing 3500 points, reaching a new high for the year, closing up 0.48% at 3509.68 points [1] - The Shenzhen Component Index and the ChiNext Index also saw gains, with the former up 0.47% and the latter up 0.22% [1] - Over 2900 stocks in the market were in the green, with significant contributions from the financial and real estate sectors [1] Financial Sector Performance - The brokerage sector showed strong performance, with Zhongyin Securities hitting the daily limit, and other firms like Hongta Securities and Northeast Securities also seeing gains [3][4] - Major banks, including Industrial and Commercial Bank of China and Agricultural Bank of China, reached new highs, with the banking sector overall showing robust growth [6][7] Real Estate Sector Activity - The real estate sector experienced a significant rise, with companies like Debi Group and Tiefa Service seeing gains of over 10% [7][8] - The Ministry of Housing and Urban-Rural Development emphasized the importance of stabilizing the real estate market and implementing effective policies to promote healthy development [7][9] Organic Silicon Sector Growth - The organic silicon sector surged, with companies like Silica Treasure Technology and Hongbo New Materials hitting their daily limits [10][11] - Recent price increases in silicon wafers, with rises between 8% and 11.7%, are expected to improve the performance of silicon wafer manufacturers [10][12] Investment Opportunities - The expansion of the "Southbound Bond Connect" to include more domestic investors is anticipated to enhance investment flexibility and yield for non-bank financial institutions [5][6] - The focus on high-quality residential development is expected to create opportunities in the housing market, aligning with government policies aimed at stabilizing the market [9]

提名委員會的職權範圍 於二零二五年六月二十四日採納 Sisram Medical Ltd 的 提名委員會職權範圍 – 1 – 釋義 1. 就本職權範圍（「 職權範圍 」）而言： 「 組織章程細則 」指本公司的組織章程細則； 「 董事會 」指本公司董事會； 「 本公司 」指Sisram Medical Ltd； 「 公司秘書 」指本公司的公司秘書； 「 董事 」指董事會成員； 「 本集團 」指本公司及其附屬公司； 「 提名委員會 」指由董事會根據此等職權範圍議決設立的提名委員會； 「 股東 」指本公司不時的股東；及 「 聯交所 」指香港聯合交易所有限公司。 成立 2. 提名委員會於二零一七年八月三十日由董事會議決設立。 成員 6. 提名委員會應委任至少一名不同性別的董事。 會議 7. 會議應於有需要時舉行，惟須最少一年舉行一次。 – 2 – 3. 提名委員會的成員應由董事會從董事中委任，成員不少於三名，其中大多數應 為獨立非執行董事。提名委員會會議的法定人數為兩名成員，其中最少一名應 為獨立非執行董事。 4. 提名委員會成員的任期最多三年，可由董事會延長，惟委員會多數成員仍須為 獨立非執行董事。 5. 提名委員 ...